AB3A.F Sarepta Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
14.78 EUR
Close of Nov 11, 2026
12.82 20.51
Market cap
EUR 1.58B
P/E
739.0x
P/B
1.23x
ROE
26.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AB3A.F undervalued?

Graham number

The Graham number of Sarepta Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sarepta Therapeutics Inc fundamental analysis

No fundamental analysis for Sarepta Therapeutics Inc yet.

Sarepta Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed…

Full company profile